Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Cellectar Biosciences, Inc. (CLRB)

1.54   0.05 (3.36%) 01-27 15:36
Open: 1.505 Pre. Close: 1.49
High: 1.5698 Low: 1.48
Volume: 31,950 Market Cap: 14(M)

Technical analysis

as of: 2023-01-27 4:43:25 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 2.01     One year: 2.25
Support: Support1: 1.39    Support2: 1.16
Resistance: Resistance1: 1.72    Resistance2: 1.92
Pivot: 1.63
Moving Average: MA(5): 1.53     MA(20): 1.64
MA(100): 2.37     MA(250): 3.92
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 16.3     %D(3): 19.1
RSI: RSI(14): 44.2
52-week: High: 7.9  Low: 0.35
Average Vol(K): 3-Month: 51 (K)  10-Days: 52 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CLRB ] has closed above bottom band by 31.7%. Bollinger Bands are 42.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 22 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.57 - 1.58 1.58 - 1.58
Low: 1.46 - 1.47 1.47 - 1.48
Close: 1.53 - 1.54 1.54 - 1.55

Company Description

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Headline News

Fri, 23 Dec 2022
Will Cellectar Biosciences Inc (CLRB) Underperform the Rest of the Stocks in the Healthcare Sector? - InvestorsObserver

Wed, 30 Nov 2022
Cellectar Biosciences Announces Shane Lea as Chief Commercial ... - GlobeNewswire

Fri, 25 Nov 2022
BIOLASE Inc (BIOL) Stock Is Down -37.04% This Week: Buy, Hold, or Sell? - InvestorsObserver

Wed, 16 Nov 2022
Cellectar Announces Resolution of Breach of Contract and Intellectual Property Dispute - Yahoo Finance

Tue, 25 Oct 2022
Cellectar Biosciences Announces Closing of Concurrent Registered Direct and Private Placement Offerings of Approximately $10.7 Million Priced At-The-Market Under Nasdaq Rules - Yahoo Finance

Fri, 21 Oct 2022
Cellectar Biosciences Announces Concurrent Registered Direct and ... - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 9 (M)
Shares Float 7 (M)
% Held by Insiders 4.8 (%)
% Held by Institutions 23.8 (%)
Shares Short 11 (K)
Shares Short P.Month 8 (K)

Stock Financials

EPS -0.41
EPS Est Next Qtl -0.21
EPS Est This Year -0.93
EPS Est Next Year -0.88
Book Value (p.s.) 1.86
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -55.8
Return on Equity (ttm) -106.4
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.9
Qtrly Earnings Growth 0
Operating Cash Flow -22 (M)
Levered Free Cash Flow -12 (M)

Stock Valuations

PE Ratio -3.79
PEG Ratio 0
Price to Book value 0.82
Price to Sales 0
Price to Cash Flow -0.65

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2018-07-16
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.